STEMI is caused by complete coronary artery occlusion and accounts for approximately 30% of ACS, requiring emergent reperfusion therapy as the cornerstone of management. [1] The following is a comprehensive clinical summary based on the 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline and supporting evidence. [2]
1. History
- Chest discomfort at rest is the most common presenting symptom (~79% men, ~74% women) — classically described as crushing, pressure, or squeezing, substernal, radiating to the left arm, jaw, or neck [1]
- Approximately 40% of men and 48% of women present with atypical or nonspecific symptoms (dyspnea, nausea, diaphoresis, unexplained weakness), either in isolation or combined with chest pain [1]
- Key HPI elements: onset, duration, quality, radiation, severity, exacerbating/relieving factors (rest, nitroglycerin), and prior episodes
- Timing: symptom onset relative to presentation is critical — reperfusion benefit is greatest within the first 12 hours [2]
- Associated symptoms: diaphoresis, nausea/vomiting, dyspnea, lightheadedness, syncope, palpitations
- Important negatives: pleuritic quality, positional component, reproducibility with palpation (suggest alternative diagnoses but do not exclude ACS)
2. Alarm Features
- Ongoing chest pain unresponsive to nitroglycerin
- Hemodynamic instability: hypotension, tachycardia, signs of cardiogenic shock (cool extremities, altered mental status, oliguria) [3]
- New heart failure symptoms: acute pulmonary edema, JVD, S3 gallop
- Syncope or near-syncope
- New systolic murmur (papillary muscle rupture, VSD) [4]
- Cardiac arrest or malignant arrhythmias (VT/VF)
- Signs of aortic dissection (tearing pain, pulse deficits, widened mediastinum) — must be excluded before anticoagulation [2]
3. Medications
Acute Treatment
- Aspirin 162–325 mg (chewed, non-enteric coated) immediately [2][5]
- P2Y12 inhibitor loading dose — ticagrelor 180 mg or prasugrel 60 mg preferred over clopidogrel for primary PCI; clopidogrel 300–600 mg if ticagrelor/prasugrel unavailable or contraindicated [2]
- With fibrinolytics: clopidogrel only (300 mg if ≤75 y; 75 mg if >75 y) [2]
- Prasugrel is contraindicated with prior stroke/TIA
- Parenteral anticoagulation: UFH (standard), bivalirudin (Class 1 alternative for PCI, reduces bleeding) [2]
- Nitroglycerin SL 0.4 mg q5min × 3 for ongoing pain; avoid in hypotension, RV infarction, recent PDE-5 inhibitor use [6]
- Morphine for refractory pain (use cautiously — may cause hypotension)
- Supplemental O₂ only if SpO₂ <90% [6]
- High-intensity statin (atorvastatin 80 mg or rosuvastatin 20–40 mg) initiated at presentation [1]
- Beta-blocker (metoprolol, carvedilol) within 24 hours if no contraindications (cardiogenic shock, acute HF, bradycardia, hypotension)
- ACE inhibitor/ARB within 24 hours, especially with anterior STEMI, HF, or LVEF ≤40%
Contraindicated medications
- NSAIDs (except aspirin) — increase cardiovascular risk
- Fondaparinux should not be used to support PCI (risk of catheter thrombosis) [2]
4. Diet
- NPO initially if catheterization is imminent
- Post-PCI: heart-healthy diet (Mediterranean-style, DASH), sodium restriction <2 g/day
- Limit saturated fats, trans fats, and added sugars
- Adequate hydration, especially post-contrast exposure
- Long-term: dietary counseling as part of cardiac rehabilitation [7]
5. Review of Systems
- Cardiovascular: chest pain, palpitations, dyspnea on exertion, orthopnea, PND, lower extremity edema, syncope
- Pulmonary: dyspnea, pleuritic pain (consider PE, pericarditis)
- GI: nausea, vomiting, epigastric pain (inferior MI can mimic GI symptoms; also assess for GI bleeding risk before anticoagulation)
- Neurologic: focal deficits (stroke as complication or aortic dissection), altered mental status (cardiogenic shock)
- Vascular: claudication, prior vascular procedures (PAD as marker of diffuse atherosclerosis)
6. Collateral History and Family History
- Collateral: time of symptom onset (critical for reperfusion window), medications taken, prior cardiac history, recent procedures or surgeries
- Family history: premature CAD (first-degree male relative <55 y, female <65 y), familial hyperlipidemia, sudden cardiac death
- Social context: cocaine/stimulant use (coronary vasospasm), smoking status, functional baseline, social support for post-discharge care
7. Risk Factors
- Traditional: hypertension, diabetes mellitus, dyslipidemia, smoking, obesity, sedentary lifestyle, family history of premature CAD [1]
- Emerging: chronic kidney disease, autoimmune/inflammatory conditions, HIV, prior radiation therapy
- Acute precipitants: cocaine/methamphetamine use, extreme physical exertion, emotional stress
- Demographics: male sex, increasing age; women tend to present later and with more atypical symptoms [8]
- Pathophysiology: ~64% due to lipid-laden plaque rupture; plaque erosion more common in women (~37% vs ~19% in men) [1]
8. Differential Diagnosis
Cannot-miss diagnoses that mimic STEMI:
- Aortic dissection — tearing pain, pulse deficits, widened mediastinum; anticoagulation is harmful
- Pulmonary embolism — pleuritic pain, dyspnea, RV strain on ECG
- Tension pneumothorax — unilateral absent breath sounds, tracheal deviation
Other causes of ST elevation on ECG: [9-11]
- Acute pericarditis — diffuse concave ST elevation, PR depression, no reciprocal changes
- Myocarditis — ST elevation in 58–70% of cases; may closely mimic STEMI [11]
- Takotsubo (stress) cardiomyopathy — apical ballooning, often post-emotional stress
- Early repolarization — concave ST elevation with J-point notching, typically in young patients
- LVH with strain pattern, LBBB, Brugada syndrome, hyperkalemia
Up to 10% of patients taken to the cath lab for presumed STEMI have non-coronary etiologies. [1]
The following figure illustrates the morphological differences in ST-elevation patterns across these conditions:
9. Past Medical History
- Prior MI, PCI, CABG, or known CAD
- Heart failure (baseline LVEF)
- Prior stroke or TIA (affects P2Y12 inhibitor selection — prasugrel contraindicated)
- Bleeding history or bleeding diathesis (affects anticoagulation strategy)
- Chronic kidney disease (contrast nephropathy risk, dose adjustments)
- Diabetes mellitus (higher risk, atypical presentations)
- Recent surgery or trauma (fibrinolytic contraindications) [2]
10. Physical Exam
Vital signs: blood pressure (both arms if dissection suspected), heart rate, respiratory rate, SpO₂
Focused exam
- Cardiovascular: S3/S4 gallop, new murmur (mitral regurgitation from papillary muscle dysfunction/rupture, VSD), JVD, peripheral perfusion (cool/mottled extremities in shock)
- Pulmonary: crackles/rales (pulmonary edema), unilateral absent breath sounds (pneumothorax)
- Abdominal: pulsatile mass (AAA), hepatomegaly (RV failure)
- Extremities: peripheral edema, pulse deficits
- Neurologic: mental status (perfusion), focal deficits (stroke)
Killip classification for bedside severity stratification
- I: No HF signs
- II: Rales, S3, JVD
- III: Pulmonary edema
- IV: Cardiogenic shock
11. Lab Studies
- Troponin (hs-cTn preferred): biomarker of choice; however, do not delay reperfusion for troponin results in confirmed STEMI [2]
- CBC: baseline hemoglobin/platelets (bleeding risk assessment)
- BMP/CMP: renal function (contrast, medication dosing), electrolytes (arrhythmia risk — K⁺, Mg²⁺)
- Coagulation studies: PT/INR, aPTT (anticoagulation management)
- Lipid panel: baseline (initiate statin)
- BNP/NT-proBNP: prognostic value, HF assessment
- Lactate: if cardiogenic shock suspected [3]
- Type and screen: if high bleeding risk or potential for CABG
- HbA1c: diabetes screening
12. Imaging
- Echocardiography (TTE): assess LV function, regional wall motion abnormalities, mechanical complications (VSD, papillary muscle rupture, free wall rupture, pericardial effusion); emergent TTE when ECG is equivocal [4][13]
- Chest X-ray: pulmonary edema, cardiomegaly, widened mediastinum (dissection), pneumothorax
- Coronary angiography: the gold standard — performed emergently as part of primary PCI [2]
- Cardiac MRI: post-acute phase for myocardial viability, scar assessment, or if MINOCA/myocarditis suspected [14]
- CT angiography is generally not indicated in confirmed STEMI but may help if dissection is suspected
13. Special Tests
- TIMI Risk Score for STEMI: predicts 30-day mortality (age, DM/HTN/angina, SBP, HR, Killip class, weight, anterior ST elevation, time to treatment)
- Modified Sgarbossa Criteria: for diagnosing MI in the setting of LBBB or ventricular pacing [13]
- Right-sided ECG leads (V3R, V4R): assess for RV infarction in inferior STEMI [2]
- Posterior leads (V7–V9): assess for posterior STEMI when anterior ST depression in V1–V3 [2][13]
- Point-of-care ultrasound (POCUS): rapid bedside assessment of cardiac function, pericardial effusion, and volume status
14. ECG
Obtain and interpret within 10 minutes of arrival (Class 1 recommendation). [2][9]
STEMI diagnostic criteria (measured at J-point, ≥2 contiguous leads): [2]
- ≥1 mm ST elevation in all leads except V2–V3
- V2–V3: ≥2 mm in men ≥40 y, ≥2.5 mm in men <40 y, ≥1.5 mm in women regardless of age
Key ECG patterns
- Reciprocal ST depression — supports STEMI diagnosis and helps differentiate from pericarditis/early repolarization [9]
- Hyperacute T waves — earliest sign, may precede ST elevation [9]
- De Winter's sign — upsloping ST depression with tall T waves in precordial leads (LAD occlusion) — warrants emergent angiography [13]
- Wellens' syndrome — biphasic or deeply inverted T waves in V2–V3 (critical LAD stenosis)
- New LBBB — not diagnostic of STEMI in isolation; use Modified Sgarbossa Criteria [2]
- ST depression V1–V3 — consider posterior STEMI; obtain posterior leads [2][13]
- ST elevation in aVR with diffuse ST depression — suggests left main or multivessel disease [9]
Serial ECGs every 15–30 minutes if initial ECG is nondiagnostic but clinical suspicion remains high. Notably, 11% of confirmed STEMI patients had an initially nondiagnostic ECG. [2]
15. Assessment
STEMI represents complete coronary artery occlusion requiring emergent reperfusion. Approximately 5% of ACS patients die before hospital discharge. [1] Severity stratification is based on:
- Killip class at presentation
- Infarct territory (anterior/LAD carries highest mortality)
- Time from symptom onset to reperfusion
- Hemodynamic status (cardiogenic shock complicates 7–10% of STEMI, with 30-day mortality ~40–45%) [15]
Atypical presentations are common in women, elderly, and diabetic patients. Mechanical complications (papillary muscle rupture, VSD, free wall rupture) are rare (<1%) but carry ~40% in-hospital mortality. [3-4]
16. Treatment Plan
The following NEJM algorithm summarizes the STEMI management pathway:
Initial Stabilization
- IV access, continuous cardiac monitoring, 12-lead ECG within 10 minutes
- Aspirin 162–325 mg chewed immediately [2]
- Supplemental O₂ only if SpO₂ <90%
- Nitroglycerin SL for ongoing pain (avoid in hypotension, RV infarction, PDE-5 inhibitor use)
Reperfusion Strategy (the critical decision)
- Primary PCI (preferred): goal FMC-to-device ≤90 minutes at PCI-capable hospitals, or ≤120 minutes if transfer required [2]
- Fibrinolytic therapy (if PCI not available within 120 min): tenecteplase preferred; full dose if <75 y, half dose if ≥75 y [1]
- After fibrinolysis → transfer for angiography within 3–24 hours [1-2]
- Review absolute/relative contraindications before administration [2]
Adjunctive Pharmacotherapy
Cardiogenic shock: emergency revascularization of culprit vessel (Class 1), consider mechanical circulatory support, invasive hemodynamic monitoring. [2-3]
17. Disposition
- All confirmed STEMI patients require admission — typically to CCU/ICU or monitored telemetry bed
- PCI-capable hospital: direct to cath lab; post-PCI monitoring in CCU
- Non–PCI-capable hospital: DIDO (door-in-door-out) goal ≤30 minutes for transfer; if PCI not achievable within 120 min, administer fibrinolytics and transfer [7]
- Cardiogenic shock or hemodynamic instability: transfer to PCI-capable center regardless of time from symptom onset [2]
- Stable, uncomplicated STEMI post-successful PCI: early discharge (48–72 hours) may be considered in select low-risk patients
- Consult cardiology/interventional cardiology emergently for all STEMI patients
- Cardiac surgery consultation for mechanical complications or anatomy requiring CABG [1]
18. Follow Up / Return Precautions
Discharge medications: DAPT (aspirin + P2Y12 inhibitor) for at least 12 months, high-intensity statin, beta-blocker, ACE inhibitor/ARB as indicated [5][7]
Cardiac rehabilitation: refer prior to discharge (Class 1, LOE A) — reduces death, MI, readmissions, and improves functional status and QOL; home-based CR is a reasonable alternative [2]
Follow-up timing
- Cardiology follow-up within 1–2 weeks post-discharge
- PCP follow-up within 1 week for medication reconciliation and risk factor management
- Echocardiography at 6–12 weeks to reassess LV function (especially if reduced at presentation)
Return precautions — instruct patients to seek immediate care for:
- Recurrent chest pain or pressure
- New or worsening shortness of breath
- Lightheadedness, syncope, or palpitations
- Signs of bleeding (blood in stool, dark stools, excessive bruising) — especially on DAPT
- Swelling in legs or sudden weight gain
Patient counseling
- Smoking cessation (most impactful modifiable risk factor)
- Medication adherence — emphasize not stopping DAPT without physician guidance (stent thrombosis risk)
- Gradual return to activity per cardiac rehabilitation guidance
- Expected recovery: most patients return to normal activities within 4–6 weeks post-uncomplicated PCI
References
1. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. — Bhatt DL, Lopes RD, Harrington RA. The Journal of the American Medical Association. 2022.
2. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Rao SV, O'Donoghue ML, Ruel M, et al. Journal of the American College of Cardiology. 2025.
3. Cardiogenic Shock After Acute Myocardial Infarction: A Review. — Samsky MD, Morrow DA, Proudfoot AG, et al. The Journal of the American Medical Association. 2021.
4. Mechanical Complications of Acute Myocardial Infarction: A Scientific Statement From the American Heart Association. — Damluji AA, van Diepen S, Katz JN, et al. Circulation. 2021.
5. Acute Myocardial Infarction. — Anderson JL, Morrow DA. The New England Journal of Medicine. 2017.
6. Acute Coronary Syndrome: Diagnosis and Initial Management. — Nohria R, Viera AJ. American Family Physician. 2024.
7. Systems of Care for ST-Segment-Elevation Myocardial Infarction: A Policy Statement From the American Heart Association. — Jacobs AK, Ali MJ, Best PJ, et al. Circulation. 2021.
8. Acute Coronary Syndromes in Premenopausal Women: A Scientific Statement From the American Heart Association. — Kovacic JC, Reynolds HR, Alasnag M, et al. Circulation. 2026.
9. Fourth Universal Definition of Myocardial Infarction (2018). — Thygesen K, Alpert JS, Jaffe AS, et al. Journal of the American College of Cardiology. 2018.
10. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part VI: Acute Ischemia/Infarction: A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; The American College of Cardiology Foundation; And the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. — Wagner GS, Macfarlane P, Wellens H, et al. Journal of the American College of Cardiology. 2009.
11. Diagnosis and Treatment of Acute Myocarditis: A Review. — Ammirati E, Moslehi JJ. The Journal of the American Medical Association. 2023.
12. Electrocardiography. — Elias Hanna Practical Cardiovascular Medicine 2e. 2022.
13. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain In the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee. — Kontos MC, de Lemos JA, Deitelzweig SB, et al. Journal of the American College of Cardiology. 2022.
14. Acute Coronary Syndromes. — Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Lancet. 2022.
15. Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association. — Henry TD, Tomey MI, Tamis-Holland JE, et al. Circulation. 2021.